Additionally, the 36-month beta value for OTLK is 0.73. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for OTLK is 14.99M and currently, short sellers hold a 13.04% ratio of that float. The average trading volume of OTLK on July 19, 2024 was 243.46K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
OTLK) stock’s latest price update
The stock of Outlook Therapeutics Inc (NASDAQ: OTLK) has decreased by -9.39 when compared to last closing price of 8.95.Despite this, the company has seen a loss of -3.22% in its stock price over the last five trading days. marketbeat.com reported 2024-07-11 that Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.
OTLK’s Market Performance
Outlook Therapeutics Inc (OTLK) has experienced a -3.22% fall in stock performance for the past week, with a 7.28% rise in the past month, and a -5.81% drop in the past quarter. The volatility ratio for the week is 7.70%, and the volatility levels for the past 30 days are at 6.64% for OTLK.. The simple moving average for the past 20 days is 4.64% for OTLK’s stock, with a -0.62% simple moving average for the past 200 days.
Analysts’ Opinion of OTLK
Many brokerage firms have already submitted their reports for OTLK stocks, with BTIG Research repeating the rating for OTLK by listing it as a “Buy.” The predicted price for OTLK in the upcoming period, according to BTIG Research is $50 based on the research report published on March 27, 2024 of the current year 2024.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see OTLK reach a price target of $3. The rating they have provided for OTLK stocks is “Buy” according to the report published on February 15th, 2024.
OTLK Trading at 6.30% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.08% of loss for the given period.
Volatility was left at 6.64%, however, over the last 30 days, the volatility rate increased by 7.70%, as shares surge +14.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.59% lower at present.
During the last 5 trading sessions, OTLK fell by -3.22%, which changed the moving average for the period of 200-days by +83.48% in comparison to the 20-day moving average, which settled at $7.80. In addition, Outlook Therapeutics Inc saw 2.92% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OTLK starting from Haddadin Yezan Munther, who purchase 1,882 shares at the price of $11.82 back on Mar 28 ’24. After this action, Haddadin Yezan Munther now owns 5,049 shares of Outlook Therapeutics Inc, valued at $22,242 using the latest closing price.
Evanson Jeff, the CHIEF COMMERCIAL OFFICER of Outlook Therapeutics Inc, purchase 62,484 shares at $0.42 during a trade that took place back on Mar 07 ’24, which means that Evanson Jeff is holding 808,459 shares at $26,243 based on the most recent closing price.
Stock Fundamentals for OTLK
The total capital return value is set at -12.1. Equity return is now at value -827.71, with -281.52 for asset returns.
Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated -0.5 points at debt to capital in total, while cash flow to debt ratio is standing at -1.3. The debt to equity ratio resting at -0.33. The interest coverage ratio of the stock is -0.0.
Currently, EBITDA for the company is -52.6 million with net debt to EBITDA at 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.07.
Conclusion
In conclusion, Outlook Therapeutics Inc (OTLK) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
